Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant FOLFIRINOX versus gemcitabine-based chemoradiotherapy for (borderline) resectable pancreatic cancer
2017-002036-17Phase 3Active
- Sponsor
- Erasmus MC
- Start
- Jun 2018
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of folinic acid, fluorouracil, irinotecan, oxaliplatin and gemcitabine in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC) (2 arms), sponsored by Erasmus MC. Primary endpoint: Overall survival. Started Jun 2018; status: active.
02
Drugs
folinic acidfluorouracilirinotecanoxaliplatingemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on 2017-002036-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002036-17.